SCHEMBL3759842

SCHEMBL3759842

CC1CCCN1N(C)C(=O)c1ccn[c]c1-c1ccccc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.33
POLB P06746 1/20 0.33
PREP P48147 1/20 0.33
LMNA P02545 2/20 0.33
KCNH2 Q12809 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
BCHE P06276 1/20 0.32
ALDH1A1 P00352 2/20 0.32
HPGD P15428 2/20 0.32
GLA P06280 1/20 0.32
HCRTR1 O43613 1/20 0.32
CYP46A1 Q9Y6A2 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
OPRK1 P41145 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
MAPK1 P28482 1/20 0.31
HTT P42858 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3762570 0.97 KDM4E (0.36) KDM4EPOLBLMNAALDH1A1HPGD
SCHEMBL3758759 0.77 KMT2A (0.50) KDM4EALDH1A1HPGDGLANPC1
SCHEMBL3769349 0.73 TRPM8 (0.47) ALDH1A1HPGDHCRTR1MEN1KMT2A
SCHEMBL3759975 0.73 TRPM8 (0.37) KDM4EALDH1A1HPGDHCRTR1NPC1
SCHEMBL3763681 0.72 KMT2A (0.42) KDM4ELMNAKCNH2ALDH1A1HPGD
SCHEMBL3764668 0.71 HPGD (0.49) LMNAALDH1A1HPGDHCRTR1MAPK1
SCHEMBL3760647 0.71 TSHR (0.54) KDM4EPOLBALDH1A1HPGDNPC1
SCHEMBL3760380 0.71 TSHR (0.50) KDM4ELMNAALDH1A1HPGDNPC1
SCHEMBL3766118 0.71 GPR119 (0.35) POLB
SCHEMBL3999416 0.71 NPC1 (0.36) LMNAALDH1A1NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA KDM4E 1014/4885POLB 2137/4885PREP 2017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.